ScholarIQanswers from OpenAlex

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders

PaperCitations, authors & open-access status

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders have?

ScholarIQcitation count

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders has 587 citations in the OpenAlex counts ScholarIQ stores.

When was Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders published?

ScholarIQyear

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders has 2017 year in the ScholarIQ index.

What is the open-access status of Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders?

ScholarIQoa status

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders has bronze oa status in the ScholarIQ index.

What is the DOI of Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders?

ScholarIQdoi

The DOI for Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders is on the source record.

What is the PMID of Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders?

ScholarIQpmid

The PMID for Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders is on the source record.

What is the OpenAlex record for Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders?

ScholarIQopenalex

The OpenAlex for Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial